Biotech Values

[Mufaso]

AKRO- Akero shares plummeted 59% on mixed NASH results and takes ENTB with it as both companies have NASH drugs sharing the same MOA (FGF21 analogue).

Shares of Akero Therapeutics (AKRO) and 89bio (ETNB) crashed Tuesday after Akero's liver-disease treatment fell short in a midstage study. AKRO stock lost half its value and ETNB stock plunged more than 24%

...Over 36 weeks, 22% to 24% of patients who received Akero's drug had at least a one-stage improvement in fibrosis compared to 14% of the placebo group. The result wasn't statistically significant.

....But, 63% of the low-dose group and 60% of the high-dose group experienced complete NASH resolution vs. just 26% of placebo recipients. That result was statistically significant.

https://www.investors.com/news/technology/akro-stock-plummets-dragging-down-etnb-stock-on-liver-disease-flop/